Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant olaparib in germline BRCA-mutated high-risk HER2-negative early breast cancer
NL-OMON59484Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of olaparib in breast cancer, sponsored by AstraZeneca. Started Oct 2014; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON59484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59484.